Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.

Pulmonary arterial hypertension (PAH) is a chronic and progressive disease that affects the pulmonary vasculature, leading to increased pulmonary vascular resistance, right ventricular dysfunction, and ultimately, right heart failure. Early identification and management of PAH is crucial to improve patient outcomes. This requires a thorough understanding of the diagnostic criteria and classification of PAH, as well as an evidence-based approach to care that incorporates guideline recommendations, latest developments, and key insights from leading professional organizations. Moreover, given the limitations of current therapies, there is a need to critically review novel treatment pathways and new/emerging therapeutic targets for PAH.

In this clinical discussion, you'll hear from two leading experts who will share recent evidence and highlights from the 2023 American College of Cardiology Annual Meeting that supports using novel agents for PAH. As part of the discussion, they also discuss how you can optimize PAH treatment plans and integrate the latest guideline recommendations in your practice.

This program discusses respiratory syncytial virus (RSV), a ubiquitous infection capable of infecting all age groups with a high probability of reinfection. However, the clinical presentation of the disease across age groups is non-specific, and clinicians often fail to identify individuals within the population at the highest risk for poor outcomes. RSV vaccination attempts have historically been unsuccessful. Multiple potential vaccines are proceeding to the late stage of development; however, there is little awareness of these potential options. This program addresses these topics, as well as vaccine hesitancy, as it is often a barrier to improving vaccination compliance, as it exists both at the provider and patient level.

This program discusses respiratory syncytial virus (RSV), a ubiquitous infection capable of infecting all age groups with a high probability of reinfection. However, the clinical presentation of the disease across age groups is non-specific, and clinicians often fail to identify individuals within the population at the highest risk for poor outcomes. RSV vaccination attempts have historically been unsuccessful. Multiple potential vaccines are proceeding to the late stage of development; however, there is little awareness of these potential options. This program addresses these topics, as well as vaccine hesitancy, as it is often a barrier to improving vaccination compliance, as it exists both at the provider and patient level.

This program discusses respiratory syncytial virus (RSV), a ubiquitous infection capable of infecting all age groups with a high probability of reinfection. However, the clinical presentation of the disease across age groups is non-specific, and clinicians often fail to identify individuals within the population at the highest risk for poor outcomes. RSV vaccination attempts have historically been unsuccessful. Multiple potential vaccines are proceeding to the late stage of development; however, there is little awareness of these potential options. This program addresses these topics, as well as vaccine hesitancy, as it is often a barrier to improving vaccination compliance, as it exists both at the provider and patient level.

This program discusses respiratory syncytial virus (RSV), a ubiquitous infection capable of infecting all age groups with a high probability of reinfection. However, the clinical presentation of the disease across age groups is non-specific, and clinicians often fail to identify individuals within the population at the highest risk for poor outcomes. RSV vaccination attempts have historically been unsuccessful. Multiple potential vaccines are proceeding to the late stage of development; however, there is little awareness of these potential options. This program addresses these topics, as well as vaccine hesitancy, as it is often a barrier to improving vaccination compliance, as it exists both at the provider and patient level.

Nonalcoholic steatohepatitis (NASH) is an epidemic with enormous health and economic implications. Join us for our chairman’s perspective on best practices to identify, screen, and refer patients. Dr. Mazen Noureddin also examines some of the emerging therapeutics that may change your approach to NASH.

This Expert Exchange webcast is designed to enhance clinicians’ awareness of the function and role of HER3 in emerging treatment strategies for non-small cell lung cancer and metastatic breast cancer.

The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant and the most recent key real-world data releases that have been published relative to the use of reversal or repletion strategies in the anticoagulated patient. This enduring activity was initially presented as a satellite symposium held during the AC Forum's 17th National Conference on Anticoagulation Therapy on April 2, 2023, in San Francisco, CA.

The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant and the most recent key real-world data releases that have been published relative to the use of reversal or repletion strategies in the anticoagulated patient. This enduring activity was initially presented as a satellite symposium held during the AC Forum's 17th National Conference on Anticoagulation Therapy on April 2, 2023, in San Francisco, CA.